Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project

Table 1 Characteristics at cART initiation

Characteristics		Number	Percent
Sex	Female	246	51.7
Age years median (IQR)		6	(2 ; 10)
Age (years)	<2	115	24.2
	2–5	113	23.7
	6–12	197	41.4
	13–17	51	10.7
Region of origin	Africa	113	23.7
	Asia	194	40.8
	Europe	118	24.8
	Other/unknown	51	10.7
Transmission risk group	Vertical	419	88.0
	IDU	1	0.2
	Heterosexual	12	2.5
	Other/unknown	44	9.2
Previous AIDS diagnosis	Yes	99	20.8
	No	375	78.8
	Unknown	2	0.4
Pretreatment CD4 cell count (/mm3) median (IQR)*		364	(294; 422)
Pretreatment CD4 cell count (/mm³)*	<200	156	37.9
	≥200 and < 350	77	19.2
	≥350 and <500	41	10.0
	≥500	138	33.5
Pretreatment HIV RNA (log₁₀ copies/mL) median (IQR)**		5.2	(4.7; 5.7)
Pretreatment HIV RNA (log₁₀ copies/mL)**	<4	36	8
	≥4 and <5	137	30.5
	≥5 and <6	214	47.7
	>6	62	13.8
HIV subtype	Non B	382	80.3
	B	63	13.2
	Unknown	31	6.5
Year of cART start	1998–1999	105	22.1
	2000–2002	57	12.0
	2003–2004	112	23.5
	2005–2006	149	31.3
	2007–2008	53	11.1
Antiretroviral drug combination	NNRTI plus ≥ 2NRTIs^a	273	57.4
	Unboosted PI plus ≥ 2NRTIs^b	139	29.2
	Boosted PI plus ≥ 2NRTIs^c	43	9.0
	Other^d	21	4.4

^aIncludes 232 who received 2 NRTIs and 41 who received 3 NRTIs. Overall, 184 were on efavirenz and 89 on nevirapine
^bIncludes 136 who received 2 NRTIs and 1 each who received 3, 4, and 5 NRTIs. 131 were on nelfinavir, 3 on indinavir, and 2 on ritonavir
^cIncludes 37 who received 2 NRTIs, 5 who received 3 NRTIs, and 1 who received 4 NRTIs. 32 were on lopinavir/ritonavir, 5 on fosamprenavir/ritonavir, 4 on indinavir/ritonavir, and one each on atazanavir or saquinavir with ritonavir
^dIncludes 10 who received (1 NNRTI plus ≥ 2NRTIs plus 1 PI or 1 boosted PI), 5 who received (2NNRTIs plus ≥ 2NRTIs), 4 who received (≥1 NRTI plus 2 PI/boosted PI), 1 who received (1 NRTI plus boosted PI plus integrase inhibitor plus fusion inhibitor), and 1 who received (1 NRTI plus 1 boosted PI plus 1 fusion inhibitor). *CD4 cell count measurements at cART initiation were available for 412 children. **Viral load measurements at cART initiation were available for 449 children

ISSN: 1471-2334